Related Experiment Video
Updated: May 7, 2026

In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity
Published on: January 29, 2018
TAB2, an important upstream adaptor of interleukin-1 signaling pathway, is subject to SUMOylation
Xiaolin Wang1, Jingjing Jiang, Yan Lu
1Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrinology and Metabolism, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, 200025, China, visit-12345@hotmail.com.
Abstract:
SUMOylation has been considered as an important mechanism to regulate multiple cellular processes, including inflammation. TAB2 (TAK1-binding protein 2) is an upstream adaptor protein in the IL-1 signaling pathway. Covalent modifications of TAB2 have not been well studied. In this study, we demonstrated that TAB2 could be modified by SUMO. Using Ubc9 (SUMO-conjugating enzyme) fusion and mutation analysis, we identified evolutionarily conserved lysine 329 as the major SUMOylation site of TAB2. PIAS3, a SUMO E3 ligase, preferentially interacted with and promoted its SUMOylation. Interestingly, block of SUMOylation by mutation of lysine 329 enhanced the activity of TAB2, as reflected by AP-1 luciferase reporter assays. Taken together, these results suggest that SUMOylation may serve as a novel mechanism for the regulation of TAB2.
More Related Videos
Related Concept Videos
The JAK-STAT Signaling Pathway
TGF - β Signaling Pathway
PI3K/mTOR/AKT Signaling Pathway
Amplifying Signals via Enzymatic Cascade
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.

